Steven Cohen's AMLX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 106,535 shares of Amylyx Pharmaceuticals, Inc. (AMLX) worth $1.48 M, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in AMLX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 3.62 M shares. Largest reduction occurred in Q1 2024, reducing 2.58 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Amylyx Pharmaceuticals (AMLX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amylyx Pharmaceuticals (AMLX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -228,465 | Reduce 68.20% | 106,535 | $13.90 |
| Q4 2025 | -2.46 M | Reduce 87.99% | 335,000 | $12.08 |
| Q3 2025 | -1.75 M | Reduce 38.49% | 2.79 M | $13.59 |
| Q2 2025 | +3.62 M | Add 394.70% | 4.54 M | $6.41 |
| Q1 2025 | +916,966 | New Buy | 916,966 | $3.54 |
| Q4 2024 | -200 | Sold Out | 0 | $0.00 |
| Q3 2024 | +200 | New Buy | 200 | $3.24 |
| Q2 2024 | -170,000 | Sold Out | 0 | $0.00 |
| Q1 2024 | -2.58 M | Reduce 93.82% | 170,000 | $2.84 |
| Q4 2023 | +2.75 M | Add 5980998.00% | 2.75 M | $14.72 |
| Q3 2023 | -7,061 | Reduce 99.35% | 46 | $18.30 |
| Q2 2023 | -317,693 | Reduce 97.81% | 7,107 | $21.57 |
| Q1 2023 | -1.8 M | Reduce 84.74% | 324,800 | $29.34 |
| Q4 2022 | +1.66 M | Add 355.70% | 2.13 M | $36.95 |
| Q3 2022 | +154,500 | Add 49.45% | 466,961 | $28.15 |
| Q2 2022 | +312,461 | New Buy | 312,461 | $19.26 |
Steven Cohen's Amylyx Pharmaceuticals Investment FAQs
Steven Cohen first purchased Amylyx Pharmaceuticals, Inc. (AMLX) in Q2 2022, acquiring 312,461 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Amylyx Pharmaceuticals, Inc. (AMLX) for 16 quarters since Q2 2022.
Steven Cohen's largest addition to Amylyx Pharmaceuticals, Inc. (AMLX) was in Q2 2025, adding 4,536,266 shares worth $29.08 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 106,535 shares of Amylyx Pharmaceuticals, Inc. (AMLX), valued at approximately $1.48 M.
As of the Q1 2026 filing, Amylyx Pharmaceuticals, Inc. (AMLX) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Amylyx Pharmaceuticals, Inc. (AMLX) was 4,536,266 shares, as reported at the end of Q2 2025.